CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.

Publication

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.

Journal Paper/Review - Jun 4, 2018

Gillison Maura L, Blumenschein George, Fayette Jerome, Guigay Joel, Colevas A Dimitrios, Licitra Lisa, Harrington Kevin J, Kasper Stefan, Vokes Everett, Even Caroline, Worden Francis, Saba Nabil F, Iglesias Docampo Lara Carmen, Haddad Robert, Rordorf Tamara, Kiyota Naomi, Tahara Makoto, Monga Manish, Lynch Mark, Li Li, Ferris Robert L

Citation

Gillison M, Blumenschein G, Fayette J, Guigay J, Colevas A, Licitra L, Harrington K, Kasper S, Vokes E, Even C, Worden F, Saba N, Iglesias Docampo L, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris R. CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. Oncologist 2018; 23:1079-1082.

Type

Journal Paper/Review (English)

Journal

Oncologist 2018; 23

Publication Date

Jun 4, 2018

Issn Electronic

1549-490X

Pages

1079-1082

Brief description/objective

Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.